for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck KGaA

MRCG.DE

Latest Trade

124.00EUR

Change

-2.75(-2.17%)

Volume

439,170

Today's Range

123.40

 - 

128.65

52 Week Range

76.22

 - 

128.65

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
126.75
Open
127.80
Volume
439,170
3M AVG Volume
9.64
Today's High
128.65
Today's Low
123.40
52 Week High
128.65
52 Week Low
76.22
Shares Out (MIL)
434.78
Market Cap (MIL)
16,381.46
Forward P/E
21.44
Dividend (Yield %)
1.03

Next Event

Merck KGaA CMD - Healthcare:R&D Update Call

Latest Developments

More

EMD Sereno Says Bavencio Pivotal Phase III Javelin Bladder 100 Results Published In The New England Journal Of Medicine

Merck Announces EUR 59 Million Antibody-Drug Conjugate Manufacturing Expansion

Merck KGaA Says Placed 1 Billion EUR Hybrid Bond

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck KGaA

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

Industry

Major Drugs

Contact Info

Frankfurter Str. 250

64293

Germany

+49.6151.720

https://www.merckgroup.com/

Executive Leadership

Wolfgang Buechele

Independent Chairman of the Supervisory Board

Stefan Oschmann

Chairman of the Executive Board and Chief Executive Officer

Michael Fletterich

Independent Vice Chairman of the Supervisory Board, Employee Representative

Marcus Kuhnert

Member of the Executive Board, Chief Financial Officer

Udit Batra

Chief Executive Officer Life Science, Member of the Executive Board

Key Stats

2.26 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

15.3K

2018

14.8K

2019

16.2K

2020(E)

17.3K
EPS (EUR)

2017

6.160

2018

5.100

2019

5.560

2020(E)

5.932
Price To Earnings (TTM)
38.80
Price To Sales (TTM)
0.97
Price To Book (MRQ)
3.13
Price To Cash Flow (TTM)
4.84
Total Debt To Equity (MRQ)
78.36
LT Debt To Equity (MRQ)
56.06
Return on Investment (TTM)
4.53
Return on Equity (TTM)
3.41

Latest News

Latest News

Merck KGaA says it has overcome production shortages in vaccine materials

* Life Science unit has invested more than 425 mln eur since 2017

Germany's Merck says it will focus on smaller takeovers

German drugs and chemicals maker Merck KGaA <MRCG.DE> said on Wednesday it would until 2022 focus on cutting its debt from the takeover of electronic materials company Versum and any acquisitions thereafter would likely be smaller ones.

Merck KGaA raises lower end of FY profit guidance range

Merck KGaA <MRCG.DE> on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.

Merck KGaA raises lower end of FY profit guidance range

Merck KGaA on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.

BRIEF-Merck Announces Opening M Lab Collaboration Center In Shanghai

* MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES OPENING OF ITS LIFE SCIENCE BUSINESS' LARGEST M LAB™ COLLABORATION CENTER IN SHANGHAI Source text for Eikon: Further company coverage: (Berlin Speed Desk)

Exclusive: EU secures potential COVID-19 drugs from Roche, Germany's Merck - source

The European Commission has struck deals with drugmakers Roche <ROG.S> and Merck KGaA <MRCG.DE> to secure supplies of experimental treatments for COVID-19, a Commission source told Reuters on Wednesday.

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA <MRCG.DE>, EU regulators said on Wednesday as they dropped the German company from their investigation.

BRIEF-Merck Receives Additional EU Statement In Proceedings Concerning Sigma-Aldrich Acquisition

* RECEIVES EU COMMISSION SUPPLEMENTARY STATEMENT OF OBJECTIONS IN THE PROCEEDINGS CONCERNING THE SIGMA-ALDRICH ACQUISITION

BRIEF-Merck KGaA: First Clinical Trial Of TLR7 And 8 Inhibitor As Treatment For Covid-19 Symptoms

* INITIATES FIRST CLINICAL TRIAL OF TLR7 AND 8 INHIBITOR AS A POTENTIAL TREATMENT FOR SEVERE SYMPTOMS OF COVID-19 INFECTION

BRIEF-Merck KGaA: EMA Validates Application For Cancer Drug Bavencio

* MERCK KGAA - EUROPEAN MEDICINES AGENCY VALIDATES APPLICATION FOR BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-Shanghai Junshi Biosciences Signs Clinical Trial Collaboration & Supply Deal With Merck KGaA

* SIGNED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA

BRIEF-Merck KGaA, Baylor College Announce Covid-19 Vaccine Collaboration

* MERCK AND BAYLOR COLLEGE OF MEDICINE COLLABORATE TO ADVANCE A VACCINE MANUFACTURING PLATFORM TO FIGHT COVID-19

Merck KGaA says profit could slip as fertility treatments shunned

Merck KGaA <MRCG.DE> said a slight decline in operating earnings was on the cards this year as the coronavirus pandemic weighs on demand for chemicals in TV screens and is putting couples off seeking the German group's fertility treatments.

Merck KGaA says profit could slip in 2020

German healthcare and chemicals company Merck KGaA flagged that a slight decline in operating earnings was on the cards this year as the coronavirus pandemic could place a significant burden on the global economy.

BRIEF-Merck Expands Production Capacity For Viral Vectors And Gene Therapies

* MERCK EXPANDS CAPACITY FOR INDUSTRIAL PRODUCTION OF VIRAL VECTORS AND GENE THERAPIES

BRIEF-Merck Is Awarded Second US Patent For CRISPR Gene-Editing Technology

* MERCK KGAA, DARMSTADT, GERMANY, AWARDED SECOND U.S. PATENT FOR CRISPR GENE-EDITING TECHNOLOGY

BRIEF-Merck Successfully Divests Allergopharma

* THE TWO PARTIES HAVE AGREED NOT TO DISCLOSE THE PURCHASE PRICE

Merck KGaA raises 2019 guidance after Versum takeover

German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up